Q: Why is the Decitabine + Zan AML trial scheduled to commence much later that the CPACS Doxorubicin + Zan trial?
Multiple choice
a) RC220 is a "new" drug and needs to demonstrate scaled safety data prior to being used more broadly in patients. The patient population in AML is far smaller than broad Doxo utilisation. Ergo, it would take far longer to demonstrate RC220's clinical safety profile in AML. Clinical safety validation (of RC220) won't need to be undertaken in future trials (AML should commence at p1b not p1a - testing the combo, not the drug).
b) The market opportunity for CPACS is at least 100 x larger than a Decitabine + Zan synergy.
c) both a & b.
d) TRUMP 2024!
RAC Price at posting:
$1.66 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)